menu
    • menu

    Company profile for Mira Pharmaceuticals

    NEW Drugs in Dev: 4
    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Sigma-Aldrich empowers scientific discovery with top-quality solutions to accelerate research, innovation, and better health worldwide.

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    TransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Mira Pharmaceuticals Inc is an early pre-clinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic THC analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. MIRA1a is being developed as the first prescription drug to target the CB1 and CB2 receptors for chronic pain and anxiety w...
    Mira Pharmaceuticals Inc is an early pre-clinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic THC analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. MIRA1a is being developed as the first prescription drug to target the CB1 and CB2 receptors for chronic pain and anxiety without the impurities of marijuana or its side effects, such as increased appetite and paranoia.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Mira PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    855 N Wolfe St, Ste 601.2
    Telephone
    Telephone
    +1 8138642562
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://mirapharmaceuticals.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/mira-pharmaceuticals-inc/?viewAsMember=true
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/MediaRe05844504

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    MIRA Pharmaceuticals Secures Worldwide Rights to MIRA-55, SKNY-1
    MIRA Pharmaceuticals Secures Worldwide Rights to MIRA-55, SKNY-1

    04 Jun 2026

    // ACCESSWIRE

    https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/mira-pharmaceuticals-secures-worldwide-exclusive-rights-to-mira-55-an-1173065

    ACCESSWIRE
    04 Jun 2026
    Share Share
    MIRA Pharmaceuticals Secures Worldwide Rights for Ketamir-2
    MIRA Pharmaceuticals Secures Worldwide Rights for Ketamir-2

    27 May 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-05-27/mira-pharmaceuticals-secures-worldwide-rights-for-ketamir-2-expanding-global-ip-portfolio-across-10

    PHARMIWEB
    27 May 2026
    Share Share
    MIRA Pharmaceuticals Reports Positive Phase 1 Data for Ketamir-2
    MIRA Pharmaceuticals Reports Positive Phase 1 Data for Ketamir-2

    14 May 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-05-14/mira-pharmaceuticals-reports-positive-unblinded-phase-1-data-for-ketamir-2

    PHARMIWEB
    14 May 2026
    Share Share
    MIRA Obesity Drug Manuscript Accepted for Review
    MIRA Obesity Drug Manuscript Accepted for Review

    13 May 2026

    // ACCESSWIRE

    https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/mira-pharmaceuticals-announces-acceptance-of-peer-reviewed-skny-1-man-1166346

    ACCESSWIRE
    13 May 2026
    Share Share
    MIRA's Mira-55 Avoids THC, Rimonabant CNS Side Effects
    MIRA's Mira-55 Avoids THC, Rimonabant CNS Side Effects

    23 Mar 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-03-23/mira-pharmaceuticals-reports-mira-55-shows-no-thc-or-rimonabant-associated-cns-side-effects-in-prec

    PHARMIWEB
    23 Mar 2026
    Share Share
    MIRA Pharmaceuticals Completes Phase 1 Dosing Of Ketamir-2
    MIRA Pharmaceuticals Completes Phase 1 Dosing Of Ketamir-2

    04 Mar 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-03-04/mira-pharmaceuticals-completes-phase-1-dosing-of-ketamir-2

    PHARMIWEB
    04 Mar 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search